Cellectar Biosciences, Inc. Resources
Patients
News & Media
Investors
Contact
Cellectar Biosciences, Inc.
Home
About
Overview
Partnerships
Management Team
Board of Directors
Platform
Overview
Posters & Publications
Product Pipeline
Overview
Iopofosine
Clinical Studies
Overview
Waldenstrom’s Macroglobulinemia Pivotal Study
Active, not recruiting
Relapsed or Refractory Select B-Cell Malignancies Clinical Study
Active, not recruiting
Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG
Recruiting
Patients
News & Media
Investors
Contact
Annual Reports
Investors
Investors
Overview
News / Events
Overview
Press Releases
IR Calendar
Email Alerts
Company Info
Overview
Profile
Presentations
Management Team
Contacts
FAQ
Financial Info
Overview
Balance Sheet
Income Statement
Cash Flow
Financial Results
Stock Data
Overview
Quote
Charts
Historical Data
SEC Filings
Overview
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Governance
Overview
Board of Directors
Board Committees
Governance Documents
Investor Tools
Email Alerts
Contacts
RSS News Feed
SEC Filings
Overview
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Filing Type:
View All
10-K
10-K/A
10KSB
10KSB/A
ARS
NT 10-K
Year:
View All
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
Date
Form
Description
PDF
XBRL
Pages
03/27/06
10KSB
Optional form for annual and transition reports of small business issuers [Section 13 or 15(d), not S-B Item 405]
Documents
EX-31.1
EX-31.2
EX-32.1
50
1
2
3
4